Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XIAP antisense · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| XIAP antisense | DRUG | 2 days loading dose followed by weekly 2hr infusion |
Inclusion Criteria * Subjects with relapsed or refractory AML, except those with APL (acute promyelocytic leukemia), that are about to receive their initial treatment for first relapse after an initial CR that lasted less than 6 months or for primary refractory AML that have an expected complete re...
XIAP antisense is an investigational small molecule being studied for acute myelomonocytic leukemia, specifically in patients with refractory or relapsed disease. It is designed to be given in combination with chemotherapy. The drug is currently in Phase 1 clinical development and is not yet approved by the FDA.
XIAP antisense targets the X-linked inhibitor of apoptosis protein (XIAP). By inhibiting XIAP, the drug aims to promote apoptosis in cancer cells, potentially enhancing the effectiveness of chemotherapy in treating acute myelomonocytic leukemia. This mechanism is being evaluated in a Phase 1 clinical trial.
XIAP antisense is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The drug is currently in Phase 1 clinical development for acute myelomonocytic leukemia.
XIAP antisense is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 trial studying the drug in combination with chemotherapy for refractory or relapsed acute myelomonocytic leukemia has been completed.
XIAP antisense has one completed Phase 1 clinical trial, identified as NCT00363974. This study evaluated the drug given with chemotherapy for refractory or relapsed acute myelomonocytic leukemia. The trial enrolled 54 participants in the United States and Canada and was not randomized or blinded.